List of Oseni drug patents

Oseni is owned by Takeda Pharms Usa.

Oseni contains Alogliptin Benzoate; Pioglitazone Hydrochloride.

Oseni has a total of 4 drug patents out of which 0 drug patents have expired.

Oseni was authorised for market use on 25 January, 2013.

Oseni is available in tablet;oral dosage forms.

Oseni can be used as method of treating diabetes comprising administering a compound such as alogliptin, method of treating diabetes comprising administering alogliptin.

The generics of Oseni are possible to be released after 04 June, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone
Jun, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in